



Clinical trial results:

MABTENANCE: International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation alone in Patients with Chronic Lymphocytic Leukemia

Summary

EudraCT number	2009-013651-29
Trial protocol	AT SK CZ BG
Global end of trial date	28 November 2017

Results information

Result version number	v1 (current)
This version publication date	13 December 2018
First version publication date	13 December 2018

Trial information

Trial identification

Sponsor protocol code	CLL-8/A Mabtenance
-----------------------	--------------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01118234
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	AGMT
Sponsor organisation address	Gentzgasse 60/20, Vienna, Austria, 1180
Public contact	Daniela Wolkersdorfer, AGMT, +43 6641422504, d.wolkersdorfer@agmt.at
Scientific contact	Richard Greil, AGMT, +43 5725525801, r.greil@salk.at

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	08 November 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	27 January 2016
Global end of trial reached?	Yes
Global end of trial date	28 November 2017
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Progression-free survival:

Clinical PFS is defined as the period from randomization until disease progression or death due to the underlying disease.

Protection of trial subjects:

Safety assessments were scheduled 3-monthly during observation/treatment phase and during follow up. Premedication prior to each infusion of rituximab was done. All patients entering this study have been previously treated with rituximab.

Background therapy:

None.

Evidence for comparator:

Treatment was compared to observation only.

Actual start date of recruitment	01 April 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Romania: 3
Country: Number of subjects enrolled	Slovakia: 35
Country: Number of subjects enrolled	Austria: 105
Country: Number of subjects enrolled	Bulgaria: 18
Country: Number of subjects enrolled	Czech Republic: 102
Worldwide total number of subjects	263
EEA total number of subjects	263

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23	0

months)	
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	152
From 65 to 84 years	111
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Patients have been recruited in 29 institutions in 5 countries (Austria, Bulgaria, Czech Republic, Slovakia and Romania). In total 263 patients were enrolled from April 2010 until December 2013.

Pre-assignment

Screening details:

Patients had to be in complete remission or partial remission (according to NCI working group guidelines, Hallek et al. 2008) after an induction treatment containing rituximab (1st line or 2nd line).

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Rituximab

Arm description:

Treatment with one infusion of rituximab every 12 weeks for a total of 8 infusions (two years). Follow up for 2 years, followed by long-term follow up until last patient last visit.

Arm type	Experimental
Investigational medicinal product name	Rituximab
Investigational medicinal product code	
Other name	Mabthera
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Treatment (one infusion of Rituximab 375 mg/m²) started in week 1, and was repeated every twelve weeks for eight consecutive cycles (+/- 14 days).

Arm title	Observation
------------------	-------------

Arm description:

Observation at 3-monthly intervals, for a period of 2 years. Follow up for 2 years, followed by long-term follow up until last patient last visit.

Arm type	No intervention
No investigational medicinal product assigned in this arm	

Number of subjects in period 1	Rituximab	Observation
Started	134	129
Completed	96	86
Not completed	38	43
Non-protocol AC treatment	1	1
Consent withdrawn by subject	1	2
Patient decision	1	-
Disease progression	10	34

Secondary malignancy	5	2
Adverse event	7	1
Unacceptable toxicity	4	-
Lost to follow-up	1	-
Died	-	2
Consecutive treatment doses missed	8	-
Protocol deviation	-	1

Baseline characteristics

Reporting groups

Reporting group title	Rituximab
Reporting group description: Treatment with one infusion of rituximab every 12 weeks for a total of 8 infusions (two years). Follow up for 2 years, followed by long-term follow up until last patient last visit.	
Reporting group title	Observation
Reporting group description: Observation at 3-monthly intervals, for a period of 2 years. Follow up for 2 years, followed by long-term follow up until last patient last visit.	

Reporting group values	Rituximab	Observation	Total
Number of subjects	134	129	263
Age categorical Units: Subjects			
In utero			0
Preterm newborn infants (gestational age < 37 wks)			0
Newborns (0-27 days)			0
Infants and toddlers (28 days-23 months)			0
Children (2-11 years)			0
Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age continuous Units: years			
median	63	63	
inter-quartile range (Q1-Q3)	55 to 69	58 to 71	-
Gender categorical Units: Subjects			
Female	34	42	76
Male	100	87	187
ECOG Units: Subjects			
ECOG 0	113	115	228
ECOG 1	21	14	35
White blood cells Units: x 10 ⁹ cells/L			
median	4.1	4.0	
inter-quartile range (Q1-Q3)	3.1 to 5.2	3.2 to 5.1	-
Neutrophils Units: x 10 ⁹ cells/L			
median	2.5	2.6	
inter-quartile range (Q1-Q3)	1.8 to 3.1	1.9 to 3.6	-
Haemoglobin Units: g/L			
median	139	140	

inter-quartile range (Q1-Q3)	131 to 149	131 to 147	-
Platelets			
Units: x 10 ⁹ platelets/L			
median	165	154	
inter-quartile range (Q1-Q3)	127 to 204	125 to 193	-

End points

End points reporting groups

Reporting group title	Rituximab
Reporting group description: Treatment with one infusion of rituximab every 12 weeks for a total of 8 infusions (two years). Follow up for 2 years, followed by long-term follow up until last patient last visit.	
Reporting group title	Observation
Reporting group description: Observation at 3-monthly intervals, for a period of 2 years. Follow up for 2 years, followed by long-term follow up until last patient last visit.	

Primary: Progression free survival

End point title	Progression free survival
End point description: This study was an event-triggered study. The final analysis was planned after 92 events. The database snapshot for the primary endpoint was done after the response assessment following the end of treatment or observation was available for the last patient and data cleaning was complete (Jan 27, 2016).	
End point type	Primary
End point timeframe: Time from randomisation to progression or death from underlying disease.	

End point values	Rituximab	Observation		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	134	129		
Units: Months				
median (confidence interval 95%)	47.0 (37.4 to 99999999)	35.5 (25.7 to 46.3)		

Statistical analyses

Statistical analysis title	Progression free survival
Statistical analysis description: Survival data were analysed using the Kaplan-Meier method and treatment groups were compared using a Cox regression model.	
Comparison groups	Rituximab v Observation
Number of subjects included in analysis	263
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.00077
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.5

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.33
upper limit	0.75

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From enrollment to final visit after 2 years of follow up. Adverse events/ serious adverse events were collected until last patient last visit (28-Nov-2017), data base snapshot was done after data cleaning (08-Nov-2018).

Adverse event reporting additional description:

During treatment/observation period all grades of infections and grade 3/4 other clinical AEs were reported. Documented grade 1 or 2 non-infectious AEs were not included in this analysis. During follow up only related SAEs were reported. All AEs (incl. SAEs) for this report come from the eCRF, therefore relationship from sponsor is not included.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	16.1
--------------------	------

Reporting groups

Reporting group title	Rituximab
-----------------------	-----------

Reporting group description:

Treatment with one infusion of rituximab every 12 weeks for a total of 8 infusions (two years).

Reporting group title	Observation
-----------------------	-------------

Reporting group description:

Observation at 3-monthly intervals, for a period of 2 years

Serious adverse events	Rituximab	Observation	
Total subjects affected by serious adverse events			
subjects affected / exposed	53 / 134 (39.55%)	33 / 129 (25.58%)	
number of deaths (all causes)	30	31	
number of deaths resulting from adverse events	4	4	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma of colon			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal cell carcinoma			

subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hodgkin's disease			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lentigo maligna			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Rectal cancer			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma			
subjects affected / exposed	1 / 134 (0.75%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of skin			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Hypertension			

subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive crisis			
subjects affected / exposed	1 / 134 (0.75%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial occlusive disease			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery stenosis			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Cholecystectomy			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Death			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fatigue			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Pyrexia			
subjects affected / exposed	7 / 134 (5.22%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	3 / 8	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 134 (0.00%)	2 / 129 (1.55%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Haematospermia			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea exertional			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epistaxis			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal septum deviation			

subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonitis			
subjects affected / exposed	1 / 134 (0.75%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sleep apnoea syndrome			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Gastrointestinal examination			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Ankle fracture			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Contusion			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Forearm fracture			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hand fracture			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infusion related reaction			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar vertebral fracture			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniscus injury			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle rupture			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periprosthetic fracture			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiation retinopathy			

subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rib fracture			
subjects affected / exposed	1 / 134 (0.75%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thoracic vertebral fracture			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound complication			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
subjects affected / exposed	0 / 134 (0.00%)	2 / 129 (1.55%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery disease			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			

subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Balance disorder			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carpal tunnel syndrome			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
subjects affected / exposed	4 / 134 (2.99%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Meningoradiculitis			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Autoimmune thrombocytopenia			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			

subjects affected / exposed	1 / 134 (0.75%)	3 / 129 (2.33%)	
occurrences causally related to treatment / all	1 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemolysis			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	2 / 134 (1.49%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Amaurosis			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerotic retinopathy			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glaucoma			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular degeneration			

subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Ascites			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			
subjects affected / exposed	1 / 134 (0.75%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine polyp			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis acute			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis necrotising			

subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Actinic keratosis			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis allergic			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Calculus ureteric			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	2 / 134 (1.49%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure acute			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Goitre			

subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyarthrititis			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylolisthesis			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abscess jaw			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	2 / 134 (1.49%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchopneumonia			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Campylobacter gastroenteritis			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Chronic sinusitis			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysentery			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas			
subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile infection			
subjects affected / exposed	1 / 134 (0.75%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes virus infection			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			
subjects affected / exposed	2 / 134 (1.49%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	2 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			

subjects affected / exposed	2 / 134 (1.49%)	2 / 129 (1.55%)	
occurrences causally related to treatment / all	1 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lobar pneumonia			
subjects affected / exposed	1 / 134 (0.75%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis aseptic			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonsillar abscess			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngitis			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	8 / 134 (5.97%)	4 / 129 (3.10%)	
occurrences causally related to treatment / all	6 / 11	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pneumonia streptococcal			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound infection			

subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			
subjects affected / exposed	2 / 134 (1.49%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	1 / 134 (0.75%)	2 / 129 (1.55%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Septic shock			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Sinusitis			
subjects affected / exposed	3 / 134 (2.24%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	2 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheobronchitis			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Hypercalcaemia			
subjects affected / exposed	1 / 134 (0.75%)	0 / 129 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			

subjects affected / exposed	0 / 134 (0.00%)	1 / 129 (0.78%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Rituximab	Observation	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	32 / 134 (23.88%)	17 / 129 (13.18%)	
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	15 / 134 (11.19%)	7 / 129 (5.43%)	
occurrences (all)	21	7	
Infections and infestations			
Bronchitis			
subjects affected / exposed	14 / 134 (10.45%)	10 / 129 (7.75%)	
occurrences (all)	21	12	
Herpes zoster			
subjects affected / exposed	0 / 134 (0.00%)	6 / 129 (4.65%)	
occurrences (all)	0	6	
Nasopharyngitis			
subjects affected / exposed	9 / 134 (6.72%)	17 / 129 (13.18%)	
occurrences (all)	1	22	
Respiratory tract infection			
subjects affected / exposed	18 / 134 (13.43%)	12 / 129 (9.30%)	
occurrences (all)	27	21	
Rhinitis			
subjects affected / exposed	16 / 134 (11.94%)	4 / 129 (3.10%)	
occurrences (all)	20	4	
Sinusitis			
subjects affected / exposed	6 / 134 (4.48%)	6 / 129 (4.65%)	
occurrences (all)	8	7	
Upper respiratory tract infection			
subjects affected / exposed	18 / 134 (13.43%)	17 / 129 (13.18%)	
occurrences (all)	29	34	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/27374465>